Cure Today2d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
MAIA Biotechnology reports promising THIO trial results for NSCLC
CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...
Hosted on MSN8d
MAIA Biotechnology announces updated data from THIO-101 trial
MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...
Morningstar1mon
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
Phase 2 pivotal trials to evaluate efficacy of THIO in combination with BeiGene’s checkpoint inhibitor (CPI) tislelizumab MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the ...
Yahoo Finance8d
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...
Nasdaq1mon
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
MAIA's preclinical results in HCC, with THIO in combination with a CPI, showed complete, durable and highly potent anti-tumor immune response. Preclinical results of THIO treatment in SCLC showed ...